A randomised, double-blind, phase III study comparing SB2, an infliximab biosimilar, to the infliximab reference product Remicade in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy
Abstract
Objectives To compare the efficacy, safety, immunogenicity and pharmacokinetics (PK) of SB2 to the infliximab reference product (INF) in patients with moderate to severe rheumatoid arthritis (RA) despite methotrexate therapy. Methods This is a phase Ill, randomised, double-blind, multinational, multicentre parallel group study.
Patients with moderate to severe RA despite methotrexate therapy were randomised in a 1:1 ratio to receive either SB2 or INF of 3 mg/kg. The primary end point was the American College of Rheumatology 20% (ACR20) response at week 30.
Inclusion of the 95% Cl of the ACR20 response difference within a +/- 15% margin was required for equivalence. Results 584 subjects were randomised into SB2 (N=291; 290 analysed) or INF (N=293).
The ACR20 response at week 30 in the per-protocol set was 64.1% in S32 versus 66.0% in INF. The adjusted rate difference was -1.88% (95% Cl -10.26% to 6.51%), which was within the predefined equivalence margin.
Other efficacy outcomes such as ACR50/70, disease activity score measured by 28 joints and European League against Rheumatism response were similar between S32 and INF. The incidence of treatment-emergent adverse events was comparable (57.6% in SB2 vs 58.0% in INF) as well as the incidence of antidrug antibodies (ADA) to infliximab up to week 30 (55.1% in S12 vs 49.7% in INF).
The PK profile was similar between S12 and INF. Efficacy, safety and PK by ADA subgroup were comparable between S12 and INF.
Conclusions SB2 was equivalent to INF in terms of ACR20 response at week 30. SB2 was well tolerated with a comparable safety profile, immunogenicity and PK to INF.